Arrowhead Research | ARWR - Equity Capital And Reserves


Arrowhead Research reported $465.53M in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
Agios Pharmaceuticals USD 1.03B 83.09M Jun/2026
Alnylam Pharmaceuticals USD 1.35B 278.74M Jun/2026
Anika Therapeutics USD 137.28M 3.38M Jun/2026
Arrowhead Research USD 465.53M 148.45M Jun/2026
Heron Therapeutics USD 6.91M 2.23M Jun/2026
Incyte USD 6.34B 721.58M Jun/2026
Ionis Pharmaceuticals USD 439.74M 51.68M Jun/2026
Ligand Pharmaceuticals USD 967.52M 29.81M Jun/2026
Merck USD 41.93B 3.94B Jun/2026
Moderna USD 6.76B 647M Jun/2026
Nektar Therapeutics USD 576.22M 486.38M Mar/2026
Novartis USD 41.95B 3.02B Jun/2026
Sarepta Therapeutics USD 1.53B 22.7M Jun/2026
TG Therapeutics USD 604.08M 20.95M Jun/2026
Ultragenyx Pharmaceutical USD -291M 55M Jun/2026
Vertex Pharmaceuticals USD 20.25B 886M Jun/2026
Xencor USD 503.23M 12.4M Jun/2026